Cellular senescence and circulating peptide measurements. Selected publications, evidence context and AUVYRON editorial interpretation.
Publication links open the journal website in a new tab. The publisher may require security verification or a subscription; PubMed provides an alternative citation and abstract.
01
Preclinical · cells and mice
Pancreatic islet senescence in experimental models
Kong BS et al. · Experimental & Molecular Medicine 25 August 2025
Study question & design
Researchers examined MOTS-c in aging pancreatic islets and in mouse models of metabolic and autoimmune dysfunction.
Reported findings
Treatment reduced several islet-senescence measures and improved glucose intolerance in the studied mouse models. Separate human measurements found lower circulating levels in people with type 2 diabetes.
Limits of interpretation
The intervention evidence is preclinical. The human comparison measured endogenous peptide levels; it was not a trial administering MOTS-c to patients.
Circulating MOTS-c in obesity and after weight loss
Yoon SH et al. · Journal of Clinical & Translational Endocrinology February 2026 · online 30 December 2025
Study question & design
The study compared circulating MOTS-c in 22 lean controls and 32 adults with obesity scheduled for bariatric surgery.
Reported findings
Levels were higher in the obesity group and associated with metabolic measurements. Circulating levels remained unchanged after postoperative weight loss in the reported follow-up.
Limits of interpretation
Associations do not establish cause or treatment response. Surgery and endogenous peptide measurements cannot be used as evidence of efficacy for a supplied MOTS-c vial.
These notes describe selected publications, not a systematic review. They provide no dosing or treatment instructions. A published study does not establish the identity, purity, safety, efficacy or regulatory approval of an AUVYRON product. For catalog presentations and the photographed vial, see the compound overview.
